Cardiology

With the global epidemic of obesity showing no signs of waning, physicians should be aware of the cardiac side effects of weight-loss drugs.

Researchers have been investigating whether PCSK9 inhibitors can protect other patients at high risk for a cardiovascular event.

At AAPA 2017 in Las Vegas, Jennifer Carlquist PA-C, ER, CAQ said that she believed clinicians are trained in medicine to think heart disease is "an old person's disease," so they don't have it on their radar for the young people (teen years through mid-30s).

Surgeons can collaborate with pharmacists to reduce medication errors.

What should the new priorities be in congenital heart disease research?

Our author says it's best to assume that any patient with RA is a ticking vascular time bomb. Which statements support that?

A review of Initial presentation and management of acute myocardial infarction.

Study results also showed that levosimendan did not positively affect secondary outcome measures compared to placebo.

Results of a new study indicate an unrecognized systolic dysfunction.

A new study published by The New England Journal of Medicine shows promising results for angiotensin II for treatment-resistant vasodilatory shock.

SGLT-2i medicines reduce heart failure hospitalization by 39%.

Even so-called “healthy obese†people have increased risk of heart failure.

Researchers studied administrative claims data from over a year.

The dual endothelin receptor antagonist caused early fluid retention.

A German study examined the intestinal microbiomes of 20 HF patients.

An incremental and tripartite approach to prevention, say researchers, will begin to shift AF disease distribution and decrease morbidity over time.

After decades of decline, heart disease mortality is on the rise again.

What are existing strategies to prevent heart disease?

What topics are important for PCPs to understand to treat their CVD patients?

Exercise training had positive anti-arrhythmic effects in patients with AF.

PCPs must be aware of all potential therapies to help reduce the burden of HF.

Treating systolic blood pressure of >120 mmHG reduces risk of acute decompensated heart failure.

A new category of cardiovascular “extreme risk” has LDL-C goals of

High BMI in midlife may lead to higher risk of hospitalization for heart failure.

A supplemental new drug application has been submitted to the US Food and Drug Administration (FDA) for 10-mg rivaroxaban as a treatment to reduce the risk of recurrent venous thromboembolism (VTE) after at least six months of standard anticoagulation therapy.

A tripartite strategy targets lifestyle change, treats CV risk factors and CV disease, and encourages more global thinking.

Richard A. Chazal, MD, who was the ACC president at the time of the of the most recent ACC conference, revealed which presented studies he believes could change medical practice in the near future. He also discussed how low LDL cholesterol level guidelines will go.

People who restrict trans fats are hospitalized less for MIs and strokes.

Slide show: Evidence for gout's role as a risk factor for heart disease is mixed. New studies add support.

Breakthrough status for a new drug to treat familial hypercholesterolemia.